The DLBCL subgroup with PDL-1+ in tumor cells was associated with unfavorable prognostic factors like the non-GCB subtype, IPI high-risk group, elevated beta2-microglobulin, resistance to standard therapy, and reduced overall survival (OS) compared with the PD-1 negative subgroup [29–32] (see Table 1). This evidence concerns the gene CD274 and neoplasm.